MGMark Greer

Mark Greer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Greer has a total of 350 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes and treatment of early detectable donor-specific antihuman leukocyte antigen antibodies after lung transplantation: Insights from a 12-year experience

    by Catharina Thomas, Sophie Kruszona, Nunzio D. de Manna, Murielle Verboom, Anke Walloschek, Michael Hallensleben, Julia Carlens, Carsten Mueller, Dmitry Bobylev, Nicolaus Schwerk, et al.

  • Open Access

    Lung transplantation for pulmonary alveolar proteinosis: a retrospective international multicentre analysis

    by Stefan Schwarz, Helmut Prosch, Erdal Yekeler, Piergiorgio Solli, Xavier Demant, Don Hayes, Masayuki Chida, Kieran Halloran, Mark Greer, Puneet Garcha, et al.

    Background: Pulmonary alveolar proteinosis (PAP) is a rare disease. Only a small number of case reports describing lung transplantation (LTx) as a treatment option for PAP have been published. Due to this limited evidence, current guidelines on LTx for PAP remain vague. To address this gap, we collected cases of LTx for PAP worldwide. Methods: 214 centres were approached to contribute any cases of LTx performed for PAP. Re-transplantations and multi-organ transplantations were excluded. Patients were divided into two groups based on the presence of PAP recurrence after LTx. Time-to-event analyses were performed using Kaplan–Meier curves and Cox proportional-hazards modelling was performed with PAP recurrence as a time-dependent covariate. Results: At a response rate of 64%, 31 centres contributed 63 patients. Most had primary PAP (n=20; 39.2%). Six patients with secondary PAP were identified (11.8%), while seven (13.7%) had congenital and 18 (35.3%) unclassified PAP. Aetiology was not specified in 12. Patients underwent transplantation at a median (interquartile range) 11 (3–17) years after initial diagnosis. Nine (15%) patients developed PAP recurrence after LTx. No significant difference was found regarding patient characteristics between the patients with versus without recurrence. Freedom from recurrence was 96.2% (1 year), 83.5% (5 years) and 70.1% (10 years) post-LTx. PAP recurrence as time-dependent covariate was not significantly associated with graft loss (hazard ratio 1.88, 95% CI 0.51–6.91; p=0.342) in a Cox proportional-hazards model. Conclusion: LTx provides excellent peri-operative and long-term outcomes for patients with end-stage PAP and should be recommended in treatment guidelines. Although recurrence of PAP occurs in ∼15% of cases, overall survival appeared unaffected in our limited dataset.


  • Open Access

    Aberrant and Ectopic Cell Populations in Restrictive Allograft Syndrome after Lung Transplantation

    by Lena M. Leiber, Leonard Christian, Lavinia Neubert, Jannik Ruwisch, Hande Yilmaz, Edith K. J. Plucinski, Linus T. Langer, Jan C. Kamp, Mark Greer, Bernd Haermeyer, et al.

    Rationale: Restrictive allograft syndrome (RAS) is a major cause of mortality following lung transplantation due to progressive fibrosis of the lung allograft with no therapeutic options. Knowledge of the cellular and molecular mechanisms driving fibrosis in RAS remains limited. Objective: To characterize the cellular and molecular changes in human RAS lungs through single-cell transcriptomic profiling. Methods: Single-nucleus RNA-sequencing (snRNA-seq) was performed in peripheral lung tissues from 15 RAS patients undergoing lung re-transplantation, and from 9 healthy control lungs. Findings were validated and extended using histologic techniques including immunofluorescence, RNA in situ hybridization, Elastica-van-Gieson immunohistochemistry, quantitative histological analyses, and micro-CT scans. Measurements and Main results: snRNA-seq analysis of RAS lungs revealed previously undescribed aberrant basaloid cells, ectopic COL15A1 + peribronchial vascular endothelial cells (pVECs), and CTHRC1 + fibrotic fibroblasts. Histologic stains disclosed distinctive distribution patterns: aberrant basaloid cells, primarily localized at the fibrotic edge, together with juxtaposed CTHRC1 + fibrotic fibroblasts and ectopic COL15A1 + pVECs form the fibrotic niche of alveolar fibroelastosis (AFE). PRX + alveolar microvasculature is partially lost in AFE areas. Micro-CT scans revealed changes from pulmonary to systemic perfusion, facilitated by COL15A1 + pVECs. Last, our data reveals potential therapeutic targets in RAS, including integrin αvβ6, activator of TGFβ. Conclusion: Considering the multifaceted differences of RAS and idiopathic pulmonary fibrosis, we revealed a surprising general principle of an entity-spanning composition of the fibrotic niche by aberrant basaloid cells localized at the fibrotic edge, ectopic COL15A1 + pVECs and CTHRC1 + fibrotic fibroblasts. This suggests a flexible but cellular pathogenesis-guided transferability of potential therapeutic approaches between progressive fibrotic lung diseases.


  • Open Access

    The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis

    by Jannik Ruwisch, Aurélie Cazes, Lena M. Leiber, Raphaël Borie, Lavinia Neubert, Leonard Christian, Vincent Thomas de Montpréville, Adam Szmul, Farah Moussa, Stijn E. Verleden, et al.

    Pleuroparenchymal fibroelastosis (PPFE) is a progressive interstitial lung disease (ILD) with defining histology of intra-alveolar fibrosis with septal elastosis (AFE), suggesting unique cellular disease processes. Here, we present a binational single-nucleus RNA sequencing atlas of PPFE, based on explanted lungs from 40 patients. Immunofluorescence microscopy, RNA in situ hybridization, micro–computed tomography (CT), and hierarchical phase-contrast (HiP) synchrotron CT provided spatial context. We identify PPFE-associated adventitial and elastofibrotic fibroblasts as key drivers of elastotic remodeling within an inflammatory microenvironment, maintained by immune cells forming tertiary lymphoid structures. Spatial mapping reveals an intriguing zonation of AFE, maintained by intercellular circuits between PPFE-associated cell types. Comparative analysis with idiopathic pulmonary fibrosis highlights CTHRC1 + fibrotic fibroblasts and aberrant basaloid cells as conserved profibrotic cellular machinery mediating collagen deposition across ILDs. This integrative atlas defines the cellular landscape of PPFE and dissects elastotic from fibrotic remodeling, providing a molecular rationale for niche-specific therapeutic strategies.


  • Open Access

    Elective Use of Intraoperative Extracorporeal Membrane Oxygenation in Patients With Pulmonary Fibrosis Reduces Primary Graft Dysfunction After Bilateral Lung Transplantation

    by Sophie Kruszona, Khalil Aburahma, Nunzio Davide de Manna, Hayan Merhej, Murat Avsar, Dmitry Bobylev, Arjang Ruhparwar, Mark Greer, Fabio Ius, Jawad Salman

    Objectives: This study presents the 5-year experience with a more liberal intraoperative extracorporeal membrane oxygenation (ECMO) elective support in patients with pulmonary fibrosis (PF) undergoing lung transplantation (LTx). Methods: Patients with PF undergoing LTx between January 2012 and January 2025 were included and sub-divided into the period before and after the implementation of a more liberal intraoperative use of ECMO support in January 2020. Outcomes were compared between elective, non-elective, and no intraoperative ECMO in both periods. Previously-identified parameters as decision criteria for elective ECMO were examined. Results: Overall, 422 PF patients underwent LTx, of whom 273 patients were transplanted before 2020 (elective ECMO, n = 52 (19%); non-elective ECMO, n = 30 (11%); no ECMO, n = 191 (70%)) and 149 patients were transplanted since 2020 (elective intraoperative ECMO, n = 98 (66%); non-elective ECMO, n = 12 (8%); no ECMO, n = 39 (26%)). After 2020, elective ECMO was increasingly used in patients with mean pulmonary arterial pressure >50 mmHg and pulmonary vascular resistance >9.4 WU. However, 8% were not identified based on these parameters and still required non-elective ECMO. Comparing pre- and post-2020, primary graft dysfunction (PGD) grade 3 72 h post-transplant between elective (17% vs 3%, P = .002), non-elective (38% vs 0%, P = .016), and no ECMO (12% vs 3%, P = .078) was significant reduced. One-year graft survival in elective (88.5% vs 95.6%), non-elective (70% vs 91.7%), and no ECMO (92.7% vs 94.9%) showed a trend towards improved survival. Conclusions: The use of a more liberal, elective intraoperative ECMO support in patients with PF led to an improvement of PGD prevalence and survival early after lung transplantation.

  • Open Access

    Spatial transcriptomics uncovers hybrid, proinflammatory, and profibrotic cellular niches in pulmonary granuloma of patients with chronic sarcoidosis

    by Leonard Christian, Hande Yilmaz, Jannik Ruwisch, Leon Giercke, Benjamin Seeliger, Jan C Kamp, Sirvan Bayraktar, Raphael Ewen, Theresa Graalmann, Jan Fuge, et al.

    Background: Sarcoidosis is a disease of unknown etiology, characterized by the formation of immune cell accumulations (granulomas) in the lung and other tissues. Chronic sarcoidosis may lead to pulmonary fibrosis. Aim: To unravel cellular niches within pulmonary granulomas of patients with chronic sarcoidosis using spatial transcriptomics. Methods: Spatial transcriptomics using the Visium platform (10x Genomics) was performed on 9 granuloma-containing lung explants from patients with sarcoidosis. Validation of gene expression was performed through immunohistofluorescence protein staining and RNA in situ hybridization. Results: Spatial gene expression covered 30,587 gene expression spots and 173 granulomas. A CD68+ macrophage niche was localized in the center of the granuloma, with a CD3+ T-cell and CD20+ B-cell niche in close proximity, surrounded by a COL3A1+ fibroblast niche. In the Central Granuloma Macrophage niche, expression of the profibrotic macrophage genes SPP1, CHIT1, and CHI3L1 was observed, genes whose expression has recently been described for macrophages in idiopathic pulmonary fibrosis. Additionally, proinflammatory macrophage genes were expressed in the Central Granuloma Macrophage niche, suggesting that macrophages were armed for lysosomal degradation and ready for phagocytosis. Inner granuloma niches showed higher expression of interferon gamma (IFN-γ)–inducible genes. Higher collagen and CTHRC1 expression were observed in fibroblast-containing granuloma niches, characteristics of profibrotic lung remodeling. Ligand-receptor analysis identified proinflammatory and profibrotic interactions between granuloma niches. Conclusion: Taken together, macrophages in the center of the sarcoidosis granuloma form an armed-and-ready, hybrid proinflammatory and profibrotic niche, supporting granuloma persistence through continuous IFN-γ stimulation and collagen expression by fibroblasts localized in the periphery of the granuloma.


  • Open Access

    Proteomic analysis of bronchoalveolar lavage fluid after lung transplantation associates stable allograft function with less lung damage at 12 months

    by Liisa Arike, Kristina Johansson, Anna Ermund, Mark Greer, Thaher Pelaseyed, Johan Westin, Gunnar C. Hansson, Jesper M. Magnusson

    Introduction: Freedom from chronic lung allograft dysfunction (CLAD) is a key objective after lung transplantation, yet predicting its onset remains challenging. This study investigated whether early proteomic changes in bronchoalveolar lavage fluid can differentiate between patients maintaining stable graft function at 36 months and those developing CLAD within the first year. Additionally, findings were compared to proteomic data from non-transplanted individuals. Methods: Bronchoalveolar lavage fluid samples were collected at 1 month and 12 months post-transplant from 43 lung transplant recipients together with clinical parameters. Proteomic analysis was performed using mass spectrometry with label-free quantification for global protein profiling and heavy-labelled peptides for absolute quantification of mucins and related proteins. Differentially expressed proteins were identified and analysed through pathway enrichment to explore biological mechanisms associated with CLAD. Results: No significant proteomic differences were detected at 1 month. By 12 months, 63 proteins were differentially expressed between patients who developed early CLAD and those with stable function. Mucin levels declined in stable patients but remained elevated in both groups compared to healthy controls. Cartilage acidic protein 1 was significantly higher in stable patients at 12 months and correlated with better pulmonary function. Pathway analysis linked several proteins altered in patients with CLAD to networks associated with lung injury and remodelling. Conclusion: Protein profiles in bronchoalveolar lavage fluid that resemble those of healthy lungs are associated with sustained graft function, while persistent expression of lung injury markers is associated with early CLAD. This suggests an adaptive process is needed for long-term post-transplant success.


  • Lung Allograft Size Matching According to Actual, Corrected, and Predicted Total Lung Capacity for Patients With Pulmonary Fibrosis

    by Maximilian Franz, Alya Mohssen, Khalil Aburahma, Nunzio Davide de Manna, Sophie Kruszona, Dietmar Boethig, Hani Alhadidi, Dmitry Bobylev, Nicolaus Schwerk, Arjang Ruhparwar, et al.

    Objectives: Donor-recipient size matching in patients with pulmonary fibrosis may be performed according to the actual total lung capacity (aTLC) as measured by body plethysmography, the corrected total lung capacity (cTLC), and the predicted total lung capacity (pTLC). However, there is still no consensus on the ideal matching total lung capacity. Therefore, we aimed to analyse post-transplant outcomes of patients with pulmonary fibrosis listed according to aTLC, cTLC, or pTLC. Methods: Patient records were retrospectively reviewed and analysed using Bayesian statistics. Patients with pulmonary fibrosis who underwent double lung transplantation without concomitant lung reduction surgery were included. Results: Between November 2017 and May 2023, among the 521 patients who underwent lung transplantation at our institution, 122 (24%) were included, with 11 (9%) forming the aTLC group, 21 (17%) forming the cTLC group, and 90 (74%) forming the pTLC group. Overall patient and graft mortality was decreased in patients who were listed according to aTLC when compared to cTLC (HR 0.11; 95% CrI 0-0.99). However, Bayesian Cox multivariable analysis revealed that this was due to the higher incidence of associated pulmonary hypertension and chronic renal failure in the cTLC group. No difference was seen in the incidence of biopsy-confirmed rejection and chronic lung allograft dysfunction. Conclusions: Our study showed that listing patients according to aTLC improved mortality when compared to listing according to cTLC, because patients listed according to cTLC had a higher preoperative morbidity.


  • Open Access

    Recurrent pulmonary alveolar proteinosis after lung transplantation: a case series

    by Dirk Westhölter, Marcel Opitz, Josefine Rawitzer, Mark Greer, Thomas Wessendorf, Sebastian Cordes, Ulrich Costabel, Christian Taube, Francesco Bonella


  • Extracorporeal membrane oxygenation as a bridge to transplant in severe pulmonary hypertension

    by Sophie Kruszona, Khalil Aburahma, Philipp Wand, Nunzio D de Manna, Murat Avsar, Dmitry Bobylev, Carsten Müller, Julia Carlens, Alexander Weymann, Nicolaus Schwerk, et al.

    Severe pulmonary hypertension is the leading lung transplantation indication in younger patients. Despite validated risk scores, their influence on lung allocation has been negligible, with continued reliance on decompensation and ECMO bridging. This single-center, retrospective study assesses outcomes of ECMO-bridging in lung transplantation for pulmonary hypertension and evaluates short-term predictability of ECMO-bridging. Pulmonary hypertension patients listed for lung transplantation between 01.2010–03.2023 were included. Peri- and post-operative course were compared dependent upon ECMO-bridging status. Bridging risk analysis within 90 days of re-evaluation included patients not requiring ECMO at listing, with listing parameters evaluated using a univariate Cox’s proportional hazard regression. In total 114/123 patients listed underwent lung transplantation. Twenty-eight required ECMO bridging. No differences in primary graft dysfunction grade 3 at 72 h (30 vs 20%; p = 0.28) or graft survival were evident (1-year: 82 vs 88%; 5-vear: 54 vs 59%; p = 0.84). ECMO-bridging resulted in longer intensive care unit stays post-lung transplant (p = 0.002), higher rates of both re-thoracotomy (p = 0.049) and vascular complications (p = 0.031). Factors increasing 90 day ECMO risk included NT-proBNP (p < 0.001), 6 min walk (p = 0.03) and O2 requirement at rest (p = 0.006). Lung transplant survival outcomes are not affected by ECMO-bridging in patients with severe pulmonary hypertension. It does however expose patients to additional risk, and efforts such as easy-to-measure parameters to pre-emptively identify patients requiring bridging to assist with effective allocation should be encouraged.